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First-line drug treatment was recorded in 573 immuno-
competent patients with visceral leishmaniasis in Italy. In
the past 12 years, the proportion of antimonial treatments
decreased from 100% to 2.8%, while the proportion of
amphotericin B treatments increased from 0% to 97.2%.
The countrywide change in therapy is a response to both
disease reemergence and increasing antimonial failure.
Z
oonotic visceral leishmaniasis is a life-threatening dis-
ease caused by the multiplication of the protozoan par-
asite Leishmania infantum in the phagocytes of the reticu-
loendothelial system. Infections are widespread in the
Mediterranean subregion, where the parasite is transmitted
in summer by the bites of phlebotomine sand flies, and
canids serve as reservoir hosts (1).
In the first half of the 20th century, visceral leishmani-
asis was a typical infantile syndrome in Italy with high
incidence in southern regions and islands. After World War
II, the incidence dropped to 10 to 20 cases per year for 4
decades; the disease reemerged with approximately 200
cases in 2000 and 2001 (Figure 1). This trend can be
explained by the following: 1) the appearance of cases in
immunocompetent adults that might be attributable to a
general decrease in acquired immunity after the reduction
of the phlebotomine-vector populations, determined by the
massive antimosquito insecticide campaigns for malaria
eradication 50 years ago (2); 2) the spreading of the dis-
ease from traditional areas of transmission to new stable
foci in central and northern regions of Italy, as evidenced
by recent colonization of these areas by sand flies and by
increased Leishmania diffusion and prevalence among the
canine reservoir (3); and 3) the occurrence of Leishmania
infections in immunosuppressed persons, such as those
co-infected with HIV (4). Incidence of visceral leishmani-
asis in these patients, however, has recently decreased after
the introduction of highly active antiretroviral therapy
(Figure 1) (5). 
Since the 1940s through 1990, meglumine antimoniate
has been the only first-line drug for visceral leishmaniasis
treatment in Italy (6). From 1991 through 1994, a total of
90 patients of all ages, representing one third of all
immunocompetent visceral leishmaniasis case-patients
reported in Italy during that period, were enrolled in clini-
cal trials of liposomal amphotericin B (L-AmB), which led
to a novel, safe, short course of visceral leishmaniasis
treatment as an alternative to meglumine antimoniate
(7,8). In the same period, other lipid-associated AmB
drugs were registered in Italy for the treatment of fungal
infections, i.e., AmB colloidal dispersion (ABCD) and
AmB lipid complex (ABLC). Because no official policy
exists for visceral leishmaniasis therapy in Italy (physi-
cians can prescribe any registered drug under their own
responsibility) and information on drug regimens used is
not included in visceral leishmaniasis case reports, we
aimed to assess whether changes have occurred, and to
what extent, in first-line drug regimens adopted in Italy
after lipid-associated AmB was introduced into clinical
practice.
The Study
A retrospective analysis was performed on data collec-
ted at the Unit of Protozoology of Istituto Superiore di
Sanità, Rome, the main reference center for visceral leish-
maniasis surveillance in Italy. Diagnosis of visceral leish-
maniasis in patients with clinically suspected cases was
routinely performed on serum and bone marrow aspirate
samples sent by hospitals, mainly from pediatrics, internal
medicine, and infectious diseases wards, from throughout
the country. If visceral leishmaniasis was confirmed, rele-
vant information on patients was recorded, which included
drug regimens used and posttherapy results. Two datasets
were analyzed: the first included information from patients
in whom leishmaniasis was diagnosed from 1986 to 1990,
i.e., before the mass enrollment of patients in the afore-
mentioned study on L-AmB; the second from patients in
whom leishmaniasis was diagnosed from 1995 to 2001,
i.e., after that study. Immunosuppressed patients (e.g., HIV
co-infected persons or transplant recipients), who usually
respond poorly to antileishmanial treatments, were not
included in our analysis. Fisher exact test was used for
comparisons.
DISPATCHES
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 9, No. 12, December 2003 1617
*Istituto Superiore di Sanità, Rome, Italy
Figure 1. Reemergence of zoonotic visceral leishmaniasis in Italy:
human cases recorded from 1987 through 2001 by passive reports
and active surveillance.For the 1986–1990 period, we recorded treatments used
for 40 patients in 22 hospitals, representing 29.2% of 137
immunocompetent persons with visceral leishmaniasis.
Fourteen (35.0%) were children <14 years of age. As
expected, all patients were treated with meglumine anti-
moniate, given at the standard dose of 20 mg pentavalent
antimony (Sbv)/kg/day for 3 to 4 weeks (6), either alone
(37 patients) or in combination with allopurinol at the daily
dose of 15 mg/kg (3 patients). Two patients treated with
meglumine antimoniate alone (5.4%) had a visceral leish-
maniasis relapse within 6 months from treatment and have
been retreated successfully with meglumine antimoniate in
combination with allopurinol.
For the 1995–2001 period, we recorded treatment infor-
mation for 533 patients, representing a large proportion
(56.4%; annual range 43.3% to 69.1%) of 945 immuno-
competent visceral leishmaniasis patients. About half were
children (267; annual range in proportion 42.1% to
64.8%). Every year, patients were referred by 19 to 42 hos-
pitals, with a range of 1 to 30 patients per hospital. Drug
regimens recorded are shown in the Table and summarized
in Figure 2. Meglumine antimoniate was the first-line drug
used in 158 patients (29.6%) at the Sbv dosages noted pre-
viously; 6 also received allopurinol (the drug combination
was used until 1997). The proportion of meglumine anti-
moniate-treated patients has steadily decreased from
55.9% in 1995 to 2.8% in 2001. AmB drugs have been the
only alternative drugs used in the remaining 375 patients
(70.4%). Of those patients, L-AmB accounted for most
regimens (348, 92.8%); this drug was administered to both
children and adults at the standard dose of 3 mg/kg/day for
5 consecutive days plus an additional 3 mg/kg dose on day
10 (7). Slight variations from this regimen (e.g., 3
mg/kg/day for 7–10 consecutive days) were recorded in
some case-patients. ABCD and ABLC were given only to
adult patients (21 and 3 cases, respectively) both at the
dosage of 2 mg/kg/day for 7 days. Thus, lipid-associated
AmB was used to treat 372 patients (69.8%). Finally, three
adult patients were treated with the conventional AmB
deoxycholate formulation (dosages unreported). The pro-
portion of patients treated with any AmB-based drugs
increased from 44.1% in 1995 to 97.2% in 2001.
We recorded the failure of drug therapy in 16 (10.1%) of
158 patients treated with meglumine antimoniate, equally
distributed in children and adults and with no association
with particular geographic location. Five patients showed
primary unresponsiveness or experienced acute toxicity,
which required suspension from treatment, while 11
patients who responded initially to treatment had a relapse
after a variable period of time (range 3–11 months). All
patients were successfully retreated with the standard L-
AmB regimen. Altogether, the rate of meglumine antimo-
niate failures recorded in 1995 to 2001 did not differ sig-
nificantly from that of the failures in 1986 to 1990.
However, the rate significantly increased in recent years,
from 3 (5.3%) of 57  in 1995 to 4 (36.4%) of 11  in 2000
(p = 0.01). Drug treatment was unsuccessful in 12 (3.2%)
of 375 AmB-treated patients, in 2 patients the infection
was unresponsive, and 10 patients had a relapse at 3 to 10
months. This rate was significantly lower than the meglu-
mine antimoniate failure rate (p = 0.002). Eight of 10
L-AmB treatments failed in children from different geo-
graphic locations. All AmB treatment failures but one
(retreated with meglumine antimoniate) were successfully
retreated with a high-dose L-AmB regimen of 3 mg/kg/day
for 10 consecutive days.
Conclusions
A range of treatment options exists in visceral leishma-
niasis, which include two pentavalent antimonials (meglu-
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Table. First-line drugs used for treatment of visceral leishmaniasis in 533 immunocompetent patients in Italy and drug treatment 
failures recorded
a 
Y  MA (%)  L-AmB  ABCD  ABLC  dAmB  Any AmB drugs (%) 




0  0  0  45 (44.1)  
1 R 




0  0  0  35 (50.0)  
1 R 
1997  26 (39.4) 
3 U, 1 R 
34 
2 R 
5  0  1  40 (60.6)  
2 R 




4  0  0  36 (72.0)  
1 R 
1999  13 (21.0) 
1 U, 1 R 
45 
2 R 
2  1  1  49 (79.0) 
2 R 
2000  11 (9.8) 
1 U, 3 R 
89 





1  101 (90.2) 
2 U, 2 R 
2001  2 (2.8)  68 
1 R 
0  1  0  69 (97.2) 
1 R 
Total  158 (29.6)  
5 U, 11 R 
348 





3  375 (70.4) 
2 U, 10 R 
aMA, meglumine antimoniate; L-AmB, liposomal amphotericin B; ABCD, amphotericin B colloidal dispersion; ABLC, amphotericin B lipid complex; dAmB, 
amphotericin B desoxycholate; U, unresponsiveness and/or acute toxicity; R, relapse. mine antimoniate and sodium stibogluconate), four formu-
lations of AmB, aminosidine (paromomycin), pentami-
dine, and the new oral agent miltefosine (9,10). For the cli-
nician, the choice of treatment depends on several factors,
such as the clinical features of the disease, as well as drug
safety, efficacy, and cost. In the absence of any official
drug policy for visceral leishmaniasis in Italy and in con-
sideration of the large sample of patients surveyed, our
study may be the first observational investigation on vis-
ceral leishmaniasis therapy at the national level from 1986
through 2001.
Results have shown a countrywide change in therapy
over the period considered. Even though the change was
relatively gradual over a 16-year period, a traditionally
effective drug (meglumine antimoniate) has been almost
fully replaced by a new compound, L-AmB, in an epi-
demiologic context of disease reemergence. Possible
explanations for this change include the following: 1)
mild or severe adverse reactions (e.g., pancreatitis, car-
diac abnormalities) are commonly seen in meglumine
antimoniate–treated patients, especially in adults, when
the recommended dosages are increased even slightly. A
recent investigation in Sicily showed that the antimony-
associated death rate was 7% among HIV-negative adults
with or without underlying diseases (11). On the other
hand, the toxicity of lipid-associated AmB drugs, es-
pecially L-AmB, was negligible in all categories of
patients at the dosages used for visceral leishmaniasis
therapy (9). 2) The efficacy of meglumine antimoniate for
the treatment of Mediterranean visceral leishmaniasis has
been high (approximately 95%) for >50 years. However,
in the past few years, meglumine antimoniate treatment
failures have increased in visceral leishmaniasis patients
from southern Europe. This treatment failure could be
attributable to the widespread use of meglumine antimo-
niate in treating infected dogs, which may have caused the
spread of L. infantum strains less susceptible to antimony
(12–14). Efficacy of AmB drugs is very high and, so far,
decreased  Leishmania susceptibility to this compound
(AmB is rarely used in veterinary practice) has not been
indicated. 3) Although L-AmB and other lipidic formula-
tions of AmB are 30- to 50-fold more expensive than meg-
lumine antimoniate for visceral leishmaniasis therapy at
the dosages reported above, in Western countries most of
the costs of treating visceral leishmaniasis are inpatient
hospitalization expenses rather than drug costs. Therefore,
short courses of 6 to 7 days, as required for L-AmB,
ABCD, or ABLC (9), are highly cost-effective if com-
pared with 21- to 28-day courses needed for meglumine
antimoniate treatment.
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